TerminatedPhase 2NCT00003316
Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
Studying Leiomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Katherine Y. Look, MDIndiana University Melvin and Bren Simon Cancer Center
- Intervention
- gemcitabine hydrochloride(drug)
- Eligibility
- 18 years · FEMALE
- Timeline
- 1998
Study locations (30)
- University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
- CCOP - Greater Phoenix, Phoenix, Arizona, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Chao Family Comprehensive Cancer Center, Orange, California, United States
- Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
- Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Indiana University Cancer Center, Indianapolis, Indiana, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Radiation Oncology Branch, Bethesda, Maryland, United States
- Tufts University School of Medicine, Boston, Massachusetts, United States
- University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003316 on ClinicalTrials.govOther trials for Leiomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07125183Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic LeiomyosarcomaUniversity of Colorado, Denver
- ENROLLING BY INVITATIONNANCT07405346A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized EfficacyUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE1NCT06957431Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaWashington University School of Medicine
- RECRUITINGPHASE2NCT07076186Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMSM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT06528769Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced LeiomyosarcomaGabriel Tinoco
- RECRUITINGPHASE2NCT06524583Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the TumourUNICANCER
- RECRUITINGPHASE2NCT06571734XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable LeiomyosarcomaNorthwestern University
- RECRUITINGPHASE1NCT06308419A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or DeletionsM.D. Anderson Cancer Center